Replies to post #114872 on Biotech Values

[jq1234]

Lemtrada is a hail-mary pass, my guess.

Do you mean Lemtrada approval as hail-mary pass? If that's the case, I would say this, if based on current data alone, Lemtrada has much much higher chance of approval than XL184 in prostate cancer. There are relatively large body of data showing Lemtrada efficacy up to this point. The question is whether it can get to $1.8b net sale.